ArticleCurrent medical imaging2026
Development and Validation of a CT-based Deep Transfer Learning Radiomic Model for Predicting Post-COVID-19 Pulmonary Fibrosis
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the efficacy of a deep transfer learning radiomic (DLR) model in predicting the 12-month risk of pulmonary fibrosis after COVID-19, which is crucial for early clinical intervention and treatment.
methodsRetrospective analysis of 260 COVID-19 patients (Dec 2022-Jan 2023) included chest CT and clinical data collection during hospitalization, with 1-year radiological follow-up. Final follow-up CT determined fibrosis status. ResNet-50-based DLR automatically segmented lesions from initial CTs. Radiomic features were extracted, filtered via Pearson’s correlation, and LASSO. Clinical predictors were identified through univariate/multivariate analyses. Seven classifiers built clinical, radiomic, DL, DLR, and nomogram models. Evaluation of performance was based on the AUC, calibration curves, and DCA, and model comparisons were made using DeLong’s test.
resultsAge and hospital stay duration were independent fibrosis predictors. Logistic regression outperformed other classifiers. The nomogram achieved test-set AUC=0.868 (95%CI:0.783–0.952), significantly surpassing the clinical feature-based model (p<0.05) but not the DLR model. DCA indicated higher clinical net benefits for DLR and the nomogram. DISCUSSION: The DLR model, based on automated segmentation technology, has advanced the prediction of post-COVID-19 fibrosis and provided an effective predictive tool for clinical radiology.
conclusionThe DLR model, leveraging automated CT lesion segmentation, effectively predicts post-COVID-19 pulmonary fibrosis, offering robust clinical utility. The nomogram integrating clinical and radiomic data enhances risk stratification but does not significantly improve upon the standalone DLR model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.